triple action glp 1 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data In the ATTAIN-1 phase 3,
Description
- - - A new systematic review and meta-analysis in Obesity Reviews has answersand they're critical for anyone treating obesity as a chronic disease
Strategic Timeline of Obesity Medications This timeline is more than a forecast, its a strategic lens into the future of obesity care
The outcome? Reduced hunger, effortless smaller portion sizes, and a metabolism optimized to burn calories faster
A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.
